Susceptibility of Candida spp. clinical isolates to antimycotics and disinfectants

被引:2
|
作者
Staniszewska, Monika [1 ]
Rozbicka, Beata [1 ]
Rajnisz, Aleksandra [1 ]
Bocian, Ewa [2 ]
Wasinska, Ewa [2 ]
Jakimiak, Bozenna [1 ]
Roehm-Rodowald, Ewa [1 ]
Kurzatkowski, Wieslaw [1 ]
Tyski, Stefan [2 ,3 ]
机构
[1] Natl Inst Hyg, Natl Inst Publ Hlth, PL-00791 Warsaw, Poland
[2] Natl Med Inst, PL-00725 Warsaw, Poland
[3] Med Univ Warsaw, PL-02091 Warsaw, Poland
来源
CENTRAL EUROPEAN JOURNAL OF BIOLOGY | 2010年 / 5卷 / 06期
关键词
Yeast susceptibility; Antifungal drugs; Disinfectants; Antiseptic; Candida spp; IN-VITRO ACTIVITIES; AMPHOTERICIN-B; BLOOD-STREAM; VORICONAZOLE; RESISTANCE; FLUCONAZOLE; CASPOFUNGIN; GLABRATA; AGENTS; EPIDEMIOLOGY;
D O I
10.2478/s11535-010-0068-3
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The incidence of candidiasis among immunocompromised patients and emergence of antimycotics resistant strains has increased significantly. The aims of this study were: to examine the in vitro activity of antimycotics and biocides against Candida clinical isolates; to detect cross-resistance of fungi to these preparations and to estimate whether disinfectants applied in hospital areas are active against clinical Candida isolates. In vitro susceptibility of 102 Candida isolates to eight antimycotics was examined by Etest and ATB Fungus. Sensitivity of these strains to four disinfectants and an antiseptic agent was tested according to EN 1275:2005. Amphotericin B, caspofungin and 5-fluorocytosine were the most effective antimycotics against all Candida isolates. Resistance to itraconazole and fluconazole was observed among C. krusei and C. glabrata. The MICs (Minimal Inhibitory Concentrations) for ketoconazole, voriconazole and posaconazole against Candida albicans ranged: 0.003 - > 32 mu g/ml and one strain was resistant to three agents tested. All analysed Candida strains were sensitive to biocides containing either chlorine, aldehyde, alcohol mixtures, glucoprotamin or chlorhexidine gluconate with isopropanol. Sensitivity to these agents was observed at concentrations lower than those concentrations recommended by manufacturers to achieve proper biocidal activity to those preparations. Our data suggest that these disinfectants can be effectively applied in clinical wards to prevent nosocomial Candida infections.
引用
收藏
页码:821 / 826
页数:6
相关论文
共 50 条
  • [1] Virulence and susceptibility patterns of clinical Candida spp. isolates from a tertiary hospital, Tanzania
    Mushi, Martha F.
    Bader, Oliver
    Bii, Christine
    Gross, Uwe
    Mshana, Stephen E.
    MEDICAL MYCOLOGY, 2019, 57 (05) : 566 - 572
  • [2] In vitro antifungal susceptibility of clinical isolates of Candida spp. from hospitalized patients
    de Resende, JCP
    de Resende, MA
    MYCOSES, 1999, 42 (11-12) : 641 - 644
  • [3] Prevalence and Fluconazole Susceptibility Profile of Candida spp. Clinical Isolates in a Brazilian Tertiary Hospital in Minas Gerais, Brazil
    Neves-Junior, Athayde
    Cartagenes-Pinto, Ana Carolina
    Rocha, Debora A. S.
    Reis de Sa, Leandro F.
    Junqueira, Maria De Lourdes
    Ferreira-Pereira, Antonio
    ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS, 2015, 87 (02): : 1349 - 1359
  • [4] Prevalence and Antifungal Susceptibility Profile of Oral Candida spp. Isolates from a Hospital in Slovakia
    Cernakova, Lucia
    Liskova, Anna
    Lengyelova, Libusa
    Rodrigues, Celia F.
    MEDICINA-LITHUANIA, 2022, 58 (05):
  • [5] Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates
    Javier Carrillo-Munoz, Alfonso
    Tur-Tur, Cristina
    Hernandez-Molina, Juan M.
    Quindos, Guillermo
    Marcos-Arias, Cristina
    Eraso, Elena
    Cardenes, Delia
    Ortiz-Maestro, Oscar
    Santos, Patricia
    Estivill, Dolors
    Guardia, Celia
    Giusiano, Gustavo
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2010, 23 (03) : 122 - 125
  • [6] Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex
    Melo, Analy S.
    Bizerra, Fernando C.
    Freymueller, Edna
    Arthington-Skaggs, Beth A.
    Colombo, Arnaldo L.
    MEDICAL MYCOLOGY, 2011, 49 (03) : 253 - 262
  • [7] Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
    Sahal, Gulcan
    Bilkay, Isil Seyis
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2018, 51 (05) : 644 - 650
  • [8] A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
    Diekema, Daniel J.
    Messer, Shawn A.
    Hollis, Richard J.
    Boyken, Linda
    Tendolkar, Shailesh
    Kroeger, Jennifer
    Jones, Ronald N.
    Pfaller, Michael A.
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (02) : 233 - 236
  • [9] Identification and in vitro antifungal susceptibility of vaginal Candida spp. isolates to fluconazole, clotrimazole, and nystatin
    Cristina Diaz, Maria
    Camponovo, Rossanna
    Araya, Ingrid
    Cerda, Ann
    Paola Santander, Maria
    Carrillo-Munoz, Alfonso-Javier
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2016, 29 (03) : 151 - 154
  • [10] ANTIFUNGAL SUSCEPTIBILITY OF ISOLATES OF CANDIDA SPP. BY DISK DIFFUSION AND BROTH MICRODILUTION
    Pedroso, Reginaldo dos Santos
    Menezes, Ralciane de Paula
    Ferreira, Joseane Cristina
    Amante Penatti, Mario Paulo
    de Sa, Walkiria Machado
    Silva Malvino, Lucivania Duarte
    Candido, Regina Celia
    Moreira, Tomaz de Aquino
    BIOSCIENCE JOURNAL, 2014, 30 (01): : 304 - 311